In the 21st century, as women lead nations such as Japan and Italy, a white supremacist has claimed that there are no female philosophers, inventors, generals, or billionaires."Men"In his recent ...
US solid state transformer developer DG Matrix has raised $60 million as part of its Series A funding, led by Engine Ventures. The latest round brings the company’s total capital raised to more than ...
PROVIDENCE, R.I. - Citizens Financial Group, Inc. (NYSE:CFG) announced Tuesday it has reached a definitive agreement to acquire substantially all assets of Matrix Capital Markets Group, Inc., a ...
Discover What’s Streaming On: With Melania and The Moment in theaters and I’m Chevy Chase and You’re Not hitting HBO Max, it’s celebrity documentary season — although, really, it feels increasingly ...
Acemagic introduces the Matrix Mini M5, a compact mini PC powered by Intel’s 14th-generation Core HX processors. The company lists the device on its official website and opens pre-orders. It comes in ...
ST. PAUL — The University of Minnesota Board of Regents voted 12-0 on Friday, Jan. 30, to approve a preliminary agreement that sets the framework for a new 10-year partnership with Fairview Health ...
Apple @ Work is exclusively brought to you by Mosyle, the only Apple Unified Platform. Mosyle is the only solution that integrates in a single professional-grade platform all the solutions necessary ...
Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...
Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer (PFE.N), opens new tab access to its technology that boosts immune responses to vaccines for use in up to ...
Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results